BIOMAT Database Logo BIOMAT Database Logo

Cystic fibrosis prevalence in the United States and participation in the Cystic Fibrosis Foundation Patient Registry in 2020. 2023

Elizabeth A Cromwell, and Joshua S Ostrenga, and Jonathan V Todd, and Alexander Elbert, and A Whitney Brown, and Albert Faro, and Christopher H Goss, and Bruce C Marshall
Cystic Fibrosis Foundation, 4550 Montgomery Ave. Suite 1100N, Bethesda, MD 20814, USA. Electronic address: ecromwell@cff.org.

The Cystic Fibrosis Foundation Patient Registry (CFFPR) collects data on individuals with cystic fibrosis (CF) in the United States (US). In 2012, the US CF population was estimated at 33,292 to 34,327 individuals, with 81-84% CFFPR participation. In this study, we update these estimates via simulation to account for uncertainty in CF incidence by race or Hispanic ethnicity, initiation of CF newborn screening (NBS) programs by state, and updated cumulative survival for CF births 1968-2020. We defined registry participation as the proportion of individuals alive as of 2020 with any prior CFFPR participation as well as the proportion with contributing data in 2019 or 2020; we summarize CFFPR participation for those born prior to 1968. We estimated the 2020 prevalent CF population between 1968-2020 to be 38,804 (95% Uncertainty Interval (UI): 38,532 to 39,065) individuals, with 77% of the prevalent CF population contributing recent data. CFFPR participation differs by age (54% of those born in 1968) and exceeds >90% of the population born in 2009 or later. We demonstrate that the CFFPR remains a valid data source generalizable to the CF population. High participation among younger individuals may reflect the success of newborn screening programs and early referral to CF care. If engagement can be sustained, the percentage of individuals participating in the CFFPR will grow over time and there is an opportunity to identify factors associated with loss to follow up among older individuals to optimize the quality of the CFFPR data.

UI MeSH Term Description Entries
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012042 Registries The systems and processes involved in the establishment, support, management, and operation of registers, e.g., disease registers. Parish Registers,Population Register,Parish Register,Population Registers,Register, Parish,Register, Population,Registers, Parish,Registers, Population,Registry
D003550 Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION. Mucoviscidosis,Cystic Fibrosis of Pancreas,Fibrocystic Disease of Pancreas,Pancreatic Cystic Fibrosis,Pulmonary Cystic Fibrosis,Cystic Fibrosis, Pancreatic,Cystic Fibrosis, Pulmonary,Fibrosis, Cystic,Pancreas Fibrocystic Disease,Pancreas Fibrocystic Diseases
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014481 United States A country in NORTH AMERICA between CANADA and MEXICO.
D015994 Incidence The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases in the population at a given time. Attack Rate,Cumulative Incidence,Incidence Proportion,Incidence Rate,Person-time Rate,Secondary Attack Rate,Attack Rate, Secondary,Attack Rates,Cumulative Incidences,Incidence Proportions,Incidence Rates,Incidence, Cumulative,Incidences,Person time Rate,Person-time Rates,Proportion, Incidence,Rate, Attack,Rate, Incidence,Rate, Person-time,Rate, Secondary Attack,Secondary Attack Rates
D015995 Prevalence The total number of cases of a given disease in a specified population at a designated time. It is differentiated from INCIDENCE, which refers to the number of new cases in the population at a given time. Period Prevalence,Point Prevalence,Period Prevalences,Point Prevalences,Prevalence, Period,Prevalence, Point,Prevalences
D015997 Neonatal Screening The identification of selected parameters in newborn infants by various tests, examinations, or other procedures. Screening may be performed by clinical or laboratory measures. A screening test is designed to sort out healthy neonates (INFANT, NEWBORN) from those not well, but the screening test is not intended as a diagnostic device, rather instead as epidemiologic. Infant, Newborn, Screening,Newborn Infant Screening,Newborn Screening,Neonatal Screenings,Newborn Infant Screenings,Newborn Screenings,Screening, Neonatal,Screening, Newborn,Screening, Newborn Infant,Screenings, Neonatal,Screenings, Newborn,Screenings, Newborn Infant

Related Publications

Elizabeth A Cromwell, and Joshua S Ostrenga, and Jonathan V Todd, and Alexander Elbert, and A Whitney Brown, and Albert Faro, and Christopher H Goss, and Bruce C Marshall
Obesity in Cystic fibrosis: prevalence, trends and associated factors data from the US cystic fibrosis foundation patient registry.
September 2022, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society,
Elizabeth A Cromwell, and Joshua S Ostrenga, and Jonathan V Todd, and Alexander Elbert, and A Whitney Brown, and Albert Faro, and Christopher H Goss, and Bruce C Marshall
The survival advantage of patients with cystic fibrosis diagnosed through neonatal screening: evidence from the United States Cystic Fibrosis Foundation registry data.
September 2005, The Journal of pediatrics,
Elizabeth A Cromwell, and Joshua S Ostrenga, and Jonathan V Todd, and Alexander Elbert, and A Whitney Brown, and Albert Faro, and Christopher H Goss, and Bruce C Marshall
Patient and Family Participation in Clinical Guidelines Development: The Cystic Fibrosis Foundation Experience.
July 2020, Journal of participatory medicine,
Elizabeth A Cromwell, and Joshua S Ostrenga, and Jonathan V Todd, and Alexander Elbert, and A Whitney Brown, and Albert Faro, and Christopher H Goss, and Bruce C Marshall
The Cystic Fibrosis Foundation Patient Registry. Design and Methods of a National Observational Disease Registry.
July 2016, Annals of the American Thoracic Society,
Elizabeth A Cromwell, and Joshua S Ostrenga, and Jonathan V Todd, and Alexander Elbert, and A Whitney Brown, and Albert Faro, and Christopher H Goss, and Bruce C Marshall
The Cystic Fibrosis Foundation Patient Registry. Design and Methods of a National Observational Disease Registry.
July 2016, Annals of the American Thoracic Society,
Elizabeth A Cromwell, and Joshua S Ostrenga, and Jonathan V Todd, and Alexander Elbert, and A Whitney Brown, and Albert Faro, and Christopher H Goss, and Bruce C Marshall
Gaps in Cystic Fibrosis Care Are Associated with Reduced Lung Function in the U.S. Cystic Fibrosis Foundation Patient Registry.
September 2023, Annals of the American Thoracic Society,
Elizabeth A Cromwell, and Joshua S Ostrenga, and Jonathan V Todd, and Alexander Elbert, and A Whitney Brown, and Albert Faro, and Christopher H Goss, and Bruce C Marshall
The Cystic Fibrosis Foundation Patient Registry as a tool for use in quality improvement.
April 2014, BMJ quality & safety,
Elizabeth A Cromwell, and Joshua S Ostrenga, and Jonathan V Todd, and Alexander Elbert, and A Whitney Brown, and Albert Faro, and Christopher H Goss, and Bruce C Marshall
Predictors of influenza vaccination in the Cystic Fibrosis Foundation patient registry, 2006 through 2007.
December 2010, Chest,
Elizabeth A Cromwell, and Joshua S Ostrenga, and Jonathan V Todd, and Alexander Elbert, and A Whitney Brown, and Albert Faro, and Christopher H Goss, and Bruce C Marshall
Outcomes of infants born during the first 9 years of CF newborn screening in the United States: A retrospective Cystic Fibrosis Foundation Patient Registry cohort study.
December 2021, Pediatric pulmonology,
Elizabeth A Cromwell, and Joshua S Ostrenga, and Jonathan V Todd, and Alexander Elbert, and A Whitney Brown, and Albert Faro, and Christopher H Goss, and Bruce C Marshall
Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation patient registry.
August 2014, Annals of internal medicine,
Copied contents to your clipboard!